The growing comprehension of the pathogenesis of celiac disease has paved the way for the exploration of alternative treatment strategies. These novel approaches are aimed at addressing the condition ...

The growing comprehension of the pathogenesis of celiac disease has paved the way for the exploration of alternative treatment strategies. These novel approaches are aimed at addressing the ...

BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...

Protagonist Therapeutics (PTGX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun ...

Quest Partners LLC boosted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 885.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 23,947 ...

Continuous research has led to new drug developments, particularly disease-modifying therapies (DMTs ... PIPE-791, GSK 3888130B, PTG-007, T 20K, BHV-8000, HuL001, Amethyst, ANK 700, Arscimed, A-005, ...

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.